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Vipin Dulam, BS,* Joshua M. Cooper, MD, FACC, FHRS,† Chethan Gangireddy, MD, MPH,†
Mohammed A. Kashem, MD, PhD,‡ Yoshiya Toyoda, MD, PhD,‡
Suresh Keshavamurthy, MD, FACS, FRCS‡x
From the *Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, †Department of
Medicine, Division of Cardiology – Cardiac Electrophysiology, Temple University Hospital,
Philadelphia, Pennsylvania, ‡Department of Surgery, Division of Cardiovascular Surgery, Temple
University Hospital, Philadelphia, Pennsylvania, and xDepartment of Cardiothoracic Surgery,
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Introduction
Pacemaker infections are one of the most distressing and
morbid complications for patients and can present a chal-
lenging management problem for physicians. Pacemaker
leads, especially those that dwell in the venous system
and inside the cardiac chambers, are prone to becoming
colonized with bacteria owing to their sizeable surface
area, the nature of their external exposed materials (usually
silicone or polyurethane) that are prone to biofilm forma-
tion, and their close association with the skin surface at
the level of the pacemaker pocket.1 Leads that cross the
tricuspid valve (TV) may be at additional risk for lead-
associated endocarditis owing to contact with infected
valvular structures, and the local environment of turbulent,
high-velocity jets.
Leadless pacemakers, on the other hand, have features that
may reduce their risk of becoming infected, including a
smaller surface area, a metal-only exposed surface, no inter-
action with the TV, and no component that has proximity to
the skin surface. Micra (Medtronic, Minneapolis, MN) is a
battery-operated leadless intracardiac pacemaker that was
designed to stay anchored inside the right ventricle, thus
reducing the infection risk of conventional pacemakers.
The cylindrical device is 26 mm long, about the size of a large
pill (a volume of 1 cm3), occupying clinically insignificant
space within the right ventricular chamber. The Micra lead-
less pacemaker is placed with a transvenous implantation
catheter via the right femoral vein, so no thoracotomy is
required for this procedure.2
We present a case where a Micra leadless pacemaker was
used to manage a challenging patient with a history of TV
endocarditis, complete heart block, and multiple pacemaker
system infections.
Case report
Our patient is a 48-year-old man who presented to our
institution with a complaint of shortness of breath. His past
medical history is significant for hepatitis C infection,
intravenous (IV) drug-related endocarditis, and a tricuspid
valvectomy in 1996. At the time of valve surgery, he devel-
oped complete heart block, became completely pacemaker
dependent, and had an epicardial pacemaker system im-
planted with an upper abdominal pacemaker pocket. In
June 2013, owing to epicardial lead malfunction, he had a
left pectoral transvenous pacemaker system implanted, and
the epicardial leads were abandoned. In June 2016, in the
context of recurrent IV drug use after an 11-year period of
abstinence, he presented with back pain and fever, and was
diagnosed with lead-associated endocarditis (methicillin-sen-
sitive Staphylococcus aureus) and spinal L5-S1 osteomye-
litis. He underwent left pectoral pacemaker system
extraction and implantation of a temporary pacemaker
system, and was started on an aggressive prolonged course
of IV antibiotics. The patient had a new permanent right
pectoral transvenous pacemaker system implanted after a
week of negative blood cultures.
Three months after the contralateral pacemaker implanta-
tion, in October 2016, the patient presented with fever, chills,
and pacemaker pocket pain and erythema. He was diagnosed
with a right pectoral pocket infection (methicillin-resistant S.
aureus), again necessitating pacemaker system removal and
use of another temporary pacing system via the right internal
jugular vein. The patient had 2 epicardial ventricular leads
(Medtronic epicardial screw-in, unipolar, model 5071) surgi-
cally implanted via a left minithoracotomy and connected to a
permanent pacemaker in the left upper quadrant of the
abdomen, because both subclavicular pocket locations had
housed infected pacemaker systems within the preceding
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few months, and also owing to the higher risk for infection of
leads in the bloodstream (Figure 1). During the surgical
epicardial lead placement, an intraoperative transesophageal
echocardiogram (TEE) revealed severe tricuspid insuffi-
ciency owing to his tricuspid valvectomy. He also had a
severely dilated right ventricle and right atrium and was
therefore advised to undergo TV replacement. The valvular
replacement surgery was planned after he recovered from
his minithoracotomy.
However, 3 months after epicardial pacemaker system
implantation, in January 2017, the patient presented again
to the emergency room, complaining of fever, chills, severe
joint pain, and purulent drainage coming from the lateral
thoracotomy wound (methicillin-resistant S. aureus). A
full-body computed tomography (CT) scan revealed
infection of his epicardial leads, along with a right psoas
muscle abscess (4.2 ! 3.5 ! 8.9 cm). The scan also
demonstrated the 2 old epicardial abandoned leads as
well as the 2 newer epicardial leads. After consultation
with both electrophysiology and cardiothoracic surgery, it
was felt that implanting yet another conventional pace-
maker would pose a high risk of infection, especially
with active abscess collections present that could cause
intermittent seeding of the bloodstream. The psoas muscle
abscess was inaccessible for CT-guided drainage, and the
patient was put on IV vancomycin and then a long course
of oral doxycycline.
When a repeat CT scan revealed resolution of the psoas
abscess several months later, a Micra leadless pacemaker
was implanted into the right ventricle in July 2017. The
delivery sheath was introduced to the right femoral vein,
advanced up the inferior vena cava to the right atrium,
and deflected to allow advancement into the right ventricle.
The Micra leadless pacemaker was deployed into the apical
portion of the right ventricular septum, with good fixation
of the anchoring tines. The retention suture was cut and
removed, thereby releasing the leadless pacemaker from
the delivery sheath assembly, which was then retracted
down to the inferior vena cava. Reliable pacing was demon-
strated from the leadless pacemaker, and the epicardial
pacemaker system was programmed to a lower pacing
rate to serve as a temporary backup device while it
remained in place.
In November 2017, 4 months after implantation of the
Micra leadless pacemaker, and with ongoing negative blood
Figure 1 Intraoperative radiograph of epicardial lead placement with a
generator placed in the hypochondrium.
Figure 2 Intraoperative photograph of the indwelling Micra (Medtronic,
Minneapolis, MN) leadless pacemaker in the right ventricle, as viewed
through the right atriotomy. The leadless pacemaker had not yet been fully
encapsulated by fibrous tissue, having only been in place for under 4 months
at the time of tricuspid valve surgery.
KEY TEACHING POINTS
 Standard pacemaker leads are prone to bacterial
adherence and chronic colonization in the setting
of bacteremia and endocarditis. Full extraction of
the pacing system is needed as part of curative
treatment when lead-associated endocarditis is
present.
 Multiple episodes of endocarditis over time can
mandate sequential removal of transvenous
hardware (including pacemaker leads) in order to
achieve definitive control of these infections. The
need for multiple lead extractions does not
preclude the possibility of long-term cure from
relapsing endocarditis.
 The Micra (Medtronic, Minneapolis, MN) leadless
pacemaker has a lower risk of bacterial colonization
than standard transvenous pacemaker leads for
several reasons, and may be an appropriate choice
for chronic pacing in patients at high risk for
bacterial endocarditis.
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cultures on oral antibiotics, the patient underwent a redo
sternotomy. He had a TV replacement with a 33 mm St.
Jude Biocor bioprosthetic valve (St. Jude Medical SJM BIO-
COR Valve), full removal of the infected epicardial pacing
system implanted in October 2016, and subtotal removal of
the epicardial portion of the 1996-abandoned epicardial
leads. During the TV replacement portion of the surgery,
we were able to visualize the Micra leadless pacemaker
deep in the right ventricle (Figure 2). An intraoperative
TEE done following valve implantation revealed the new
valve was well functioning and seated appropriately.
The patient had 1 more bout of bacteremia with
methicillin-resistant S. aureus in June 2018, and a TEE was
performed to confirm that there were no vegetations on the
Micra device. The patient was treated successfully with 6
weeks of IV daptomycin. He has been free of infection for
the past 2 years, with the leadless pacemaker remaining in
place. He is doing well clinically and is actively enrolled in
a drug rehabilitation program.
Discussion
Pacemaker lead infection is a major cause of morbidity and
mortality and is particularly problematic in pacemaker-
dependent patients. Sohail and colleagues3 found that there
was a significant increase in mortality following infection
of cardiovascular implantable electronic devices. Another
group, Johansen and colleagues,4 showed, in their retrospec-
tive study, that the risk of infection after 2 years of cardiac
pacemaker implant could be up to 9.5%. Of note was
Kirkfeldt and colleagues’5 retrospective study showing that
the risk of infection in the case of device replacement and
revision is between 2- and 4-fold higher than the risk after
initial implantation.
Amidst these published studies and discussions, the
question arises as to what needs to be done to avoid recurrent
device infections. Adding to this concern are the patients at
disproportionately higher risk of bloodstream infections,
such as active IV drug users who are still in the process of
seeking treatment for their addiction.
Figure 3 Serial chest radiographs demonstrating some of the active pacemaker systems used in this patient over the years, with the active pacemaker
generator(s) highlighted in red. A: Left pectoral transvenous dual-chamber pacemaker. B: Right pectoral transvenous dual-chamber pacemaker. C: Temporary
single-chamber ventricular externalized pacemaker via the right internal jugular vein. D: Epicardial single-chamber pacemaker. E: Leadless pacemaker (primary
functioning pacemaker) and epicardial single-chamber pacemaker (set for backup pacing). F: Leadless pacemaker after epicardial pacing system was explanted.
Note that the original abdominal pacemaker system and the temporary externalized pacing system that was in place between panels A and B are not pictured.
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In the case of our patient, his history of IV drug use and
severe valvular endocarditis many years ago had warranted
a tricuspid valvectomy. The TV is known to be a nidus for
infection in IV drug use patients.6 IV antibiotics are the first
line of treatment for TV infections, and typically can be
curative without the need for surgical intervention. Recurrent
bloodstream infection, persistent valvular vegetations, and
valve leaflet destruction usually warrant a more aggressive
surgical approach. One of these surgical approaches (espe-
cially in known IV drug users) is a tricuspid valvectomy,
which was first performed by Arbulu and colleagues7 in the
early 1980s. Arbulu and colleagues had found in their
practice that the actuarial survival in 53 patients 22 years
post valvectomy was 64%. Surprisingly, the severe tricuspid
regurgitation was well tolerated in most patients but did cause
low cardiac output syndrome in about one-third of those
patients owing to right ventricular dilation and systolic
dysfunction.7
As seen in this case, our patient was able to survive almost
20 years with few cardiac complications post tricuspid
valvectomy. Eventually, however, the severe tricuspid regur-
gitation did call for a TV replacement. His clinical course
became much more complex when transvenous pacemaker
leads were implanted, serving as a nidus for bloodstream
infection perpetuation. He had done well for 17 years with
an epicardial pacemaker system in place, but during the 4
years after a transvenous pectoral pacemaker was implanted,
he underwent 7 pacing system–related procedures and was
sequentially paced by 6 different temporary and permanent
pacing systems (Figure 3).
We were finally able to circumvent the problem of
recurrent device system infections by selecting a technology
that eliminated the dominant predisposing factor for infec-
tion—the pacemaker leads that provided a robust surface
for bacterial adhesion and biofilm formation, and that served
as a physical link between the heart and the subcutaneous
space. The Micra leadless pacemaker has several advantages
over traditional pacemaker systems that may reduce the risk
for device-related infection. With a leadless pacemaker, there
is no subcutaneous pocket; there is minimal handling of the
device during implantation; the exposed surface is only
parylene-coated titanium, in contrast to standard pacemakers
that include the silicone or polyurethane outer insulation of
the leads; the surface area of a leadless pacemaker exposed
to the bloodstream is w620 mm2, in contrast to w3500
mm2 of exposed intravascular lead surface with a single-
chamber pacemaker (a dual-chamber pacemaker would
have approximately double that surface area in the blood-
stream); and the Micra leadless pacemaker undergoes
extensive or complete fibrous encapsulation, which protects
it from direct bloodstream exposure.8,9 In addition,
transvenous pacemaker leads traverse the TV, which can
interfere with valve function and also interact with the tissue
that most often becomes infected during right-sided endocar-
ditis. In contrast, the leadless pacemaker sits in the apical
portion of the right ventricle and does not interact with
the TV.
The Micra leadless pacemaker has been shown to have
63% less major complications than the transvenous
pacemaker systems in a study conducted by El-Chami and
associates.10 The same group also showed that in a study of
720 patients who had the Micra pacemaker implanted, only
21 developed serious infectious events; but none of them
had vegetation on the Micra pacemaker, and they were
successfully managed with antibiotics and device removal
was not necessary.
Leadless pacemakers might therefore be particularly
useful in patients with high risk of infection, including IV
drug users. The latest model of leadless pacemaker to be
approved by the US Food and Drug Administration can func-
tion in the VDD mode, thereby tracking atrial activity and
maintaining atrioventricular synchrony.11 Future innovations
will no doubt include a leadless pacing platform that can
perform biventricular pacing as well. This case demonstrates
how leadless pacemaker technology can be leveraged to
reduce infectious complications in a high-risk patient. This
patient was able to move forward with his life and seek
long-term help to overcome drug addiction with the cycle
of infection being broken.
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